Atai posts $26M loss, but progresses on psychedelic clinical trials

Green Market Report The clinical-stage biopharmaceutical company said it has enough cash to reach the milestones it laid out for 2025. New York-based Atai Life Sciences (Nasdaq: ATAI) reported a net loss of $26.3 million for the third quarter, down year-over-year from its net income of $43.3 million, but the clinical-stage biopharmaceutical company also noted it’s well-positioned […]